- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Akili starts enrolment for trial of ADHD digital medicine treatment
6 May 2016 • Author: Victoria White, Digital Content Producer
Akili Interactive Labs has started enrolment for its pivotal STARS-ADHD trial that will evaluate the safety and efficacy of the company’s proprietary platform, Project: EVO, for the treatment of children with Attention Deficit Hyperactivity Disorder (ADHD).
This large-scale pivotal trial marks an important inflection point in the advancement of digital medicine as a clinically-validated treatment for diagnosed patient populations.
The mechanics of the Project: EVO platform are designed to directly target an individual’s core ability to process multiple streams of information, which has the potential to change specific neural networks and improve attention, inhibition and working memory. STARS-ADHD is a double-blind, randomised, controlled, parallel-group, interventional trial to evaluate the effects of Project: EVO on attentional functioning and symptoms in ADHD-diagnosed children. In a recent open-label study, Project: EVO improved attention, inhibition and working memory in children with ADHD. Akili hopes to further validate the benefits of Project: EVO through the STARS-ADHD pivotal trial, which has been in piloting phase since November.
“Strong clinical potential”
If the STARS-ADHD trial meets its endpoints, the company plans to seek approval from the United States Food and Drug Administration for this potential first-in-class treatment. Akili has been conducting multiple clinical trials of its platform across a variety of patient populations including autism spectrum disorder (in collaboration with Autism Speaks), depression, Alzheimer’s disease (in collaboration with Pfizer) and traumatic brain injury, and it is also actively exploring clinical collaborations in other neurodegeneration indications.
“Project: EVO has demonstrated strong clinical potential in children with ADHD,” said Eddie Martucci, Ph.D., Co-founder and Chief Executive Officer of Akili. “The high-bar and rigor of a pivotal trial is an important next step toward clinically validating Project: EVO as a treatment. This validation is critical for doctors, patients and parents to have confidence in the safety and efficacy of this drug-free approach.”
The STARS-ADHD study aims to enrol a minimum of 300 children aged 8 to 12 years who have been diagnosed with ADHD.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics